Organon (OGN.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow - Longbridge

Quote List Quote List

Event Tracking

Dec10

Barclays Upgrades Organon & Co. Rating to 'Strong Sell'

12:58

Nov25

Organon & Co. to Attend Piper Sandler Healthcare Conference

12:30

Nov17

FDA Approves Organon and Fosun Henlius' POHERDY as First Perjeta Biosimilar in the US

10:30

Nov13

Organon & Co's Executive Chair Carrie Smith Cox Acquires Shares

21:06

Nov11

U.S. Bank Securities and Piper Sandler Maintain Sell Ratings for Organon

11:42

Nov10

Organon released FY2025 Q3 earnings on November 10 Pre-Market EST, actual revenue USD 1.602 B (forecast USD 1.575 B), actual EPS USD 0.61

14:30

Schedules & Filings

Schedules

Filings

Dec11

Distribution Plan(EST)

Cash dividend 0.02 USD

Nov20

Distribution Plan(EST)

Cash dividend 0.02 USD

Distribution Plan(EST)

Cash dividend 0.02 USD

View More

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change

View More